Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
To the Editor We read the recent article by Glassman and Melia1 with great interest. The authors recommend that careful consideration should be given in ophthalmic clinical trials to enrollment of both eyes when possible and highlight aspects of study design to consider. We support these recommendations but also strongly advise consideration of 2 additional aspects of study design when considering whether the methods should involve randomization of 1 eye or 2 eyes.
Bunce C, Wormald R. Considerations for Randomizing 1 Eye or 2 Eyes. JAMA Ophthalmol. 2015;133(10):1221. doi:10.1001/jamaophthalmol.2015.2757
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: